Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eurofins Scientific SE (ERFSF)
Luxembourg City, LU, LU
Eurofins Scientific SE, along with its affiliated companies, delivers a broad spectrum of analytical testing and laboratory solutions globally. The firm utilizes an extensive repertoire of approximately 200,000 analytical techniques, designed to assess various product attributes such as safety, identification, makeup, genuineness, source, trackability, and cleanliness. Its offerings span numerous sectors. These include agro-science, encompassing biological evaluations, consumer, human, and environmental safety assessments, product chemical analysis, regulatory guidance, and seed services. The company also handles general agro testing. Its assurance division provides product inspections, audits, certifications, training, and advisory services for items across food, consumer goods, healthcare, and cosmetics industries. Other specialized areas are biopharma and clinical diagnostics. Furthermore, Eurofins conducts comprehensive consumer product testing, covering compliance, audits, examinations, certifications, inspections, training programs, and digital media and cybersecurity solutions for a diverse range of sectors. It also specializes in cosmetics and personal care product analysis, and environmental testing for substances like water, air, soil, waste, and other materials. Food and feed testing is another key segment, addressing concerns such as allergens, GMOs, grain quality, meat composition, nanomaterials, pesticides, and residual DNA. The company's extensive food-related portfolio also includes audit and certification services, authenticity verification, carbohydrate analysis, consulting, detection of dioxins and persistent organic pollutants (POPs), food irradiation checks, labeling compliance, legal guidance, heavy metal screening, identity preservation, mealtime analysis, molecular and microbiology testing, mycotoxin detection, nutritional profiling, organic contaminant analysis, packaging and migration studies, radioactivity testing, rapid testing methods, sensory and consumer research, various training initiatives, veterinary drug residue screening, and vitamin content analysis. Beyond these, Eurofins offers expertise in forensic science, genomics, maritime applications, materials and engineering, REACH compliance, and advanced technologies. The company maintains a significant global presence, operating roughly 900 laboratories across 54 nations. Established in 1987, its main office is situated in Luxembourg City, Luxembourg.
Based on only 1 article — low confidence
- Eurofins Scientific: Director/PDMR Shareholding Business Wire
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.25% | -3.17% | +7.62% | -11.19% | +3.67% | -0.94% | +8.39% | +10.47% | -29.08% | +186,179,387.18% | +46,544,771.79% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Diagnostics & Research: +7.9%+4.9% Q4'25: +11.4% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+21.5% Q4'25: +83.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+7.2% Q4'25: +6.8% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+11.2% ★ Q4'25: +9.3% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%+7.2% ★ Q4'25: +12.3% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%-3.9% ★ Q4'25: -5.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×3.75× Q4'25: 2.15× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 1 EPS Ana. |
Dec 2027 12 Rev. Ana. 1 EPS Ana. |
Dec 2028 6 Rev. Ana. 1 EPS Ana. |
Dec 2029 11 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.95B
est: 2.10B (-7.2%)
|
2.54B
est: 2.68B (-5.2%)
|
2.97B
est: 3.56B (-16.6%)
|
3.78B
est: 4.33B (-12.8%)
|
4.56B
est: 5.09B (-10.3%)
|
5.44B
est: 6.61B (-17.7%)
|
6.72B
est: 7.46B (-10.0%)
|
6.71B
est: 7.21B (-7.0%)
|
6.51B
est: 7.20B (-9.5%)
|
6.95B
est: 6.96B (-0.1%)
|
7.29B
est: 7.30B (-0.2%)
|
7.55B
7.34B – 7.70B
+3.3% YoY
|
7.98B
7.47B – 8.33B
+5.7% YoY
|
8.55B
8.31B – 8.72B
+7.2% YoY
|
9.34B
9.08B – 9.53B
+9.3% YoY
|
| EBITDA |
319.96M
est: 440.85M (-27.4%)
|
484.52M
est: 561.21M (-13.7%)
|
521.62M
est: 747.51M (-30.2%)
|
656.80M
est: 909.03M (-27.7%)
|
864.90M
est: 1.07B (-18.9%)
|
1.27B
est: 1.39B (-8.1%)
|
1.54B
est: 1.56B (-1.5%)
|
1.35B
est: 1.51B (-10.6%)
|
1.22B
est: 1.51B (-19.4%)
|
1.37B
est: 1.41B (-3.0%)
|
1.45B
est: 1.48B (-2.1%)
|
1.53B
1.49B – 1.56B
+3.3% YoY
|
1.62B
1.51B – 1.69B
+5.7% YoY
|
1.73B
1.68B – 1.77B
+7.2% YoY
|
1.89B
1.84B – 1.93B
+9.3% YoY
|
| EBIT |
185.85M
est: 288.84M (-35.7%)
|
311.67M
est: 367.70M (-15.2%)
|
305.13M
est: 489.76M (-37.7%)
|
355.30M
est: 595.60M (-40.3%)
|
369.00M
est: 698.92M (-47.2%)
|
904.40M
est: 907.95M (-0.4%)
|
1.15B
est: 1.03B (+12.3%)
|
885.60M
est: 991.43M (-10.7%)
|
552.70M
est: 989.39M (-44.1%)
|
897.80M
est: 880.99M (+1.9%)
|
818.69M
est: 924.91M (-11.5%)
|
955.86M
928.99M – 974.78M
+3.3% YoY
|
1.01B
945.22M – 1.05B
+5.7% YoY
|
1.08B
1.05B – 1.10B
+7.2% YoY
|
1.18B
1.15B – 1.21B
+9.3% YoY
|
| Net Income |
87.32M
est: 166.55M (-47.6%)
|
174.00M
est: 218.45M (-20.4%)
|
216.77M
est: 283.75M (-23.6%)
|
223.90M
est: 338.56M (-33.9%)
|
195.20M
est: 368.74M (-47.1%)
|
539.40M
est: 677.31M (-20.4%)
|
782.60M
est: 1.03B (-23.7%)
|
610.20M
est: 740.98M (-17.6%)
|
310.20M
est: 544.30M (-43.0%)
|
406.40M
est: 567.94M (-28.4%)
|
474.82M
est: 665.38M (-28.6%)
|
697.33M
671.84M – 715.27M
+4.8% YoY
|
812.92M
783.21M – 833.84M
+16.6% YoY
|
948.57M
913.90M – 972.98M
+16.7% YoY
|
1.02B
980.85M – 1.04B
+7.3% YoY
|
| SGA |
30.42M
est: 17.95M (+69.5%)
|
38.36M
est: 22.85M (+67.9%)
|
48.36M
est: 30.44M (+58.9%)
|
89.90M
est: 37.01M (+142.9%)
|
52.50M
est: 43.43M (+20.9%)
|
38.20M
est: 56.43M (-32.3%)
|
60.30M
est: 63.72M (-5.4%)
|
39.40M
est: 61.61M (-36.1%)
|
135.70M
est: 61.49M (+120.7%)
|
—
est: 49.65M (-100.0%)
|
—
est: 52.12M (-100.0%)
|
53.87M
52.35M – 54.93M
+3.3% YoY
|
56.92M
53.27M – 59.44M
+5.7% YoY
|
61.00M
59.28M – 62.20M
+7.2% YoY
|
66.67M
64.80M – 67.99M
+9.3% YoY
|
| EPS |
0.57
est: 0.86 (-33.4%)
|
0.87
est: 1.12 (-22.5%)
|
1.05
est: 1.46 (-28.0%)
|
1.26
est: 1.74 (-27.6%)
|
1.10
est: 1.90 (-42.0%)
|
2.90
est: 3.48 (-16.7%)
|
4.09
est: 5.27 (-22.5%)
|
3.17
est: 3.81 (-16.8%)
|
1.61
est: 2.80 (-42.5%)
|
2.13
est: 3.04 (-29.9%)
|
2.64
est: 3.56 (-25.8%)
|
3.73
3.59 – 3.82
+4.8% YoY
|
4.35
4.19 – 4.46
+16.6% YoY
|
5.07
4.89 – 5.20
+16.7% YoY
|
5.44
5.25 – 5.58
+7.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-01 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gilles G. Martin | Chairman of the Board & Chief Executive Officer | 3M | — |
| Valerie Hanote | Executive Director | 536.7K | female |
| Francois Vigneau | Senior Vice President of Food & Feed Testing - Western Europe | — | male |
| Gabriel Julia | Senior Vice President of Clinical Diagnostics Europe | — | male |
| Joachim Reichelt | Senior Vice President of Food & Feed Testing Europe | — | male |
| Laurent Lebras | Group Administration & Chief Financial Officer | — | male |
| Timothy S. Oostdyk | Executive Vice President of BioPharma, Genomics & Agrosciences Services North America | — | — |
| Bernard Wang | Head of Investor Relations | — | male |
| Yvoine Remy | Senior Vice President of Environment Testing Europe | — | female |
| David W. Bryant | Senior Vice President of Strategic Business Development North America | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ERFSF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
